Case Report: Reversible myelodysplastic syndrome secondary to sodium valproate in an epileptic child - Takeaways - MDSpire

Case Report: Reversible myelodysplastic syndrome secondary to sodium valproate in an epileptic child

  • By

  • Hongyu Huang

  • Jiao Chen

  • Lei Ye

  • Dan Yu

  • June 17, 2026

  • 0 min

Share

  • 1

    A 9-year-old boy developed reversible myelodysplastic syndrome after 6 months of sodium valproate therapy for epilepsy.

  • 2

    The patient experienced pancytopenia with significant reductions in hemoglobin and platelet counts, confirmed by bone marrow examination.

  • 3

    Reducing the sodium valproate dose led to normalization of hematological parameters and resolution of dysplastic features within 3 months.

  • 4

    The case emphasizes the dose-dependent nature of VPA-induced myelodysplastic syndrome and its reversibility with appropriate management.

  • 5

    Vigilant hematological monitoring is crucial in pediatric patients receiving sodium valproate to prevent serious complications.

Original Source(s)

Case Report: Reversible myelodysplastic syndrome secondary to sodium valproate in an epileptic child

  • by Hongyu Huang, Jiao Chen, Lei Ye, Dan Yu

  • June 17, 2026

Related Content

The regulatory roles of dysregulated lactate dehydrogenase A in anti-tumor immunity within immune cells

Multimodal fusion of EHR and ECG based on deep learning for predicting new-onset coronary heart disease in cancer patients

2026 AACR Renal Cell Carcinoma Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the renal cell carcinoma clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min